Category: Pharma & Biotech

Abattis Announces Successful Completion of Acquisition of Gabriola Green Farms

SHARE THIS POST VANCOUVER, BRITISH COLUMBIA / March 2, 2018 / Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE: ATT / OTC: ATTBF) is pleased to announce that, further to its news release dated February 27, 2018, it has completed its acquisition (the “Acquisition”) of a 90% ownership interest in Gabriola Green Farms Inc. (“Gabriola”). Gabriola is a British Columbia company that has applied for a license to produce (an “LP”) under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) on Gabriola Island, one of the gulf islands located in the Strait of Georgia off the coast of British Columbia. Gabriola Island has a consistent temperature and humidity level, which makes it well suited to greenhouse growing.“We are excited to complete our acquisition of Gabriola. Gabriola’s anticipated LP will complete our suite of downstream offerings and be the highlight of our growth into a full-service cannabis company,” stated Rob Abenante, Abattis President and CEO.Gabriola currently has plans for an approximately 26,000 square-foot production facility to produce medical-grade marijuana located on 18 acres in the agricultural land reserve on Gabriola Island, BC. The facility will include a level 8 security vault. Gabriola’s production facilities are expected to be constructed in two phases: • Phase 1 – Buildout of its 6,000-square-foot state-of-the-art facility, consistent with ACMPR standards.• Phase 2 – Upon completion of the Phase 1 buildout, Gabriola will build...

Read More

Revive Therapeutics Announces Results for the Three and Six Months Ended December 31, 2017

SHARE THIS POST TORONTO, Feb. 27, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel cannabinoid solutions, today announced its results for the three and six months ended December 31, 2017. The unaudited condensed interim financial statements and management’s discussion and analysis for the period may be viewed on SEDAR at www.sedar.com. Operational Highlights • During the three months ended December 31, 2017, the Company announced:• Entered into Research Collaboration with Sanyal Biotechnology for Liver Diseases;• Positive Results of its Novel Cannabinoid Delivery Technology;• Appointment of Bernie Doyle, as Technical Advisor to Support Development of Medical Cannabis Patient Focused Program Enabled by Blockchain and AI Technology;• Successful Final Results of Novel Cannabinoid Delivery Technology Unlocking Commercialization Opportunities in the Medical Cannabis and Pharmaceutical Sectors; • Update on Development of Datametrex Artificial Intelligence Component in Blockchain Enabled Patient-Focused Program for Medical Cannabis Sector; and• Entered into Collaboration Agreement with Health Canada Licensed Dealer for Medical Cannabis and US FDA Approved Laboratory.Financial Highlights• Cash and cash equivalents at December 31, 2017 totaled $1,408,789 (June 30, 2017 – $1,768,676).• The net loss for the three and six months ended December 31, 2017 was $434,210 and $876,206, respectively (three and six months ended December 31, 2016 – $271,013 and $628,717 respectively).• The Company’s research costs for the...

Read More

Pivot Pharma Completes Acquisition of California-Based ERS Holdings, LLC

SHARE THIS POST VANCOUVER, British Columbia, Feb. 27, 2018 (GLOBE NEWSWIRE) — via NetworkWire – Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”) is pleased to announce that the Company has completed the acquisition of ERS Holdings, LLC (“ERS”), a privately-held California company. As previously announced on December 20, 2017, ERS has developed a patented technology called “RTIC” Ready-To-Infuse-Cannabis (the “Patent”), relating to the transformation of cannabis oil into powder for infusion into a variety of food and beverage products such as capsules, K-Cups, stick packs, baked mixes, liquid shots, protein shakes, topicals, lotions, and bottled beverages. ERS has also filed several continuation patents that would allow cannabis powder to be combined with other health and wellness products such as natural sleep-aids, cold medications and vitamins. Invented by Ross Franklin and Ed Rosenthal, the Patent “relates generally to methods and compositions of matter for enabling concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages or food by combining cannabis oil with a starch powder or starch-derived powder. Embodiments also relate to a variety of culinary uses for the stabilized, emulsified, flavorless concentrated cannabis oil powder.” Additionally, Mr. Patrick J. Rolfes has been appointed President of ERS Holdings, LLC, a wholly-owned subsidiary of Pivot. Mr. Rolfes will focus on monetizing the intellectual property (“IP”) and has already received expressions of interest from multi-national beer...

Read More

Lexaria Enters Licensing Agreement with Cannabis Edibles Infusion Company

SHARE THIS POST Kelowna, British Columbia – February 27, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) a drug delivery platform innovator, announces it has entered a definitive technology licensing agreement (the “Agreement”) with Los Angeles-based, privately-held Biolog, Inc. (“Biolog”) whereby Lexaria is providing its patented DehydraTECHTM technology to empower a unique set of next-generation food and beverage cannabis infusion products to be sold in the United States. Biolog, Inc. has separately acquired rights to patented technologies for a unique line of manufactured dissolvable infusion products designed for ease of use and precise per-unit ingredient dosing. Biolog intends to launch new products of this type to deliver DehydraTECHTM enabled CBD from hemp and/or vitamins in products available nationwide. Biolog will also launch new DehydraTECHTM enabled products in those states where it is permissible to do so delivering cannabinoids from cannabis. All product lines will offer superior palatability and bioabsorption, as well as fast action powered by DehyrdaTECHTM. Biolog has acquired 5-year exclusive rights to use Lexaria’s DehydraTECHTM technology for these particular applications within the United States for an undisclosed sum and a royalty on revenue generated on products sold utilizing DehyrdaTECHTM.“The versatility of Lexaria’s DehyrdaTECHTM technology is witnessed through its adoption to deliver vitamins in a nationally-available consumer product, or cannabinoids in many U.S. states,” said Chief Executive Officer Chris Bunka. “Biolog’s products are...

Read More

GW Pharmaceuticals Receives Orphan Drug Designation from the European Medicines Agency (EMA) for Cannabidiol for the Treatment of Tuberous Sclerosis

SHARE THIS POST LONDON and CARLSBAD, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for cannabidiol (CBD) for the treatment of tuberous sclerosis (TS). GW is currently recruiting a Phase 3 clinical trial of Epidiolex® (cannabidiol) as an adjunctive therapy for the treatment of seizures associated with TS, with data expected in the second half of 2018. Subject to positive results, GW expects to submit regulatory applications in 2019 for Epidiolex in TS in both the U.S. and Europe. TS is multisystem, genetic disease that causes benign tumors to grow in the brain and on other vital organs. TS can be life threatening in patients with severe symptoms, including drug resistant seizures and kidney failure. Up to 80 to 90% of individuals with TS will develop epilepsy during their lifetime, with onset typically in childhood. The seizures are often severe, and up to two-thirds of TS patients do not respond adequately to available medical therapies. There are significant co-morbidities associated with TS including cognitive impairment, autism spectrum disorders, developmental delay with severe learning disability and neurobehavioral disorders in individuals with TS. “GW‘s decision to evaluate Epidiolex in patients with tuberous...

Read More

GB Sciences, Inc. Enters A New Market by Signing a Contract Farming Agreement for the Development of Boutique Hemp Genetics with the Colorado Hemp Project

SHARE THIS POST LAS VEGAS, Feb. 27, 2018 /CNW/ — GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce a new agreement with the Colorado Hemp Project to develop and cultivate boutique genetics and new strains of hemp which will provide the key ingredient in proprietary CBD formulations. The mission statement of the Colorado Hemp Project is: an organic hemp farm consulting agency that works with local farmers and municipalities across the globe to bring hemp cultivars and resources to the communities that need it the most, with the sole intention of healing the planet by accelerating the establishment of local, sustainable hemp farms and companies everywhere. GB Sciences believes that hemp will provide an important palette upon which important compounds can be created, and believes that, ultimately, hemp will provide a relatively inexpensive source of important and beneficial cannabinoids. GB Sciences will breed CBD into the genetics of the hemp plants and then analyze and optimize results. Kevin Kuethe, COO GB Sciences, said: “This arrangement with the superb growers at the Colorado Hemp Project will give us the ability to manipulate genetics in a way that creates rare and beneficial plants, providing us with the necessary link between the research on the one hand and the realization of custom boutique hemp genetics on the other.” “Wild” Bill Billings, co-founder of the Colorado Hemp Project with daughter Danielle, comments:...

Read More